IMFINZI® Regimen Shows Improved Survival in Early-Stage Gastric and GEJ Cancers AstraZeneca’s innovative perioperative treatment combining IMFINZI® (durvalumab) with standard chemotherapy has shown significant improvements in survival outcomes for patients with resectable, early-stage gastric and gastroesophageal junction (GEJ) cancers. In…
Bristol Myers Squibb Gets EC Approval for Opdivo® + Yervoy® in Advanced Hepatocellular Carcinoma Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval for the combination of Opdivo® (nivolumab) and Yervoy® (ipilimumab) as a…
Proteintech Unveils Next-Gen 3D Epitope Mapping to Boost Life Sciences Research Proteintech, a global leader in antibody and life science solutions, is proud to announce the launch of enhanced product characterization for primary antibody targets on its website (ptglab.com). The…
AAD 2025: Almirall Presents Early-Stage Pipeline and Real-World Evidence on Tirbanibulin for AK Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, showcased five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting. These presentations…
Scribe Therapeutics Presents Epigenetic X-Repressor Data at 2025 Keystone Symposium Scribe Therapeutics Inc. (Scribe), a leading genetic medicines company leveraging the power of CRISPR technology to transform human health, recently presented groundbreaking data on its Epigenetic Long-Term X-Repressor (ELXR) technology…
Auna Signs Five-Year Deal to Enhance Oncology Services in Monterrey Auna S.A. (NYSE: AUNA), a leading Latin American healthcare company with operations in Mexico, Peru, and Colombia, has announced a significant step in strengthening its oncology services in Mexico. The…
Sensorion Completes Patient Enrollment in NOTOXIS Phase 2a Trial of SENS-401 Sensorion (FR0012596468 – ALSEN), a clinical-stage biotechnology company focused on developing novel therapies for hearing loss, has announced the completion of patient enrollment in its NOTOXIS Phase 2a clinical…
Reflow Medical Extends Global Presence with Launch of New European Subsidiary Reflow Medical, Inc., a pioneer in developing advanced medical devices for complex cardiovascular conditions, has revealed the establishment of its European subsidiary in Landsberg am Lech, Germany. This strategic…
Ventus Therapeutics Highlights Caspase-4/5 as Promising Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies for immunological, inflammatory, and neurological disorders, has recently announced the publication of an article in the…
Sensus Healthcare to Showcase Products at AAD Annual Meeting Sensus Healthcare, Inc. (Nasdaq: SRTS), a leader in non-invasive and cost-effective treatments for skin conditions, will showcase its complete line of Superficial Radiotherapy (SRT) products—including the SRT-100®, SRT-100+, and SRT-100 Vision™…
Neupath Health Launches Arthrosamid® for Knee Osteoarthritis in North America NeuPath Health Inc. (TSXV:NPTH), a leading provider of chronic pain treatment through its network of clinics, has announced the first-ever injection of Arthrosamid in North America at its Mississauga, Ontario…
bioAffinity Technologies Plans $4 Million Cost Cut to Boost CyPath® Lung Sales bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive testing for early-stage lung cancer and other lung diseases, has outlined its latest strategic actions aimed…